about
High-dose intravenous immunoglobulins: a promising therapeutic approach for idiopathic systemic capillary leak syndromeAnalysis of the genome to personalize therapy for melanomaInterleukin-7 and interleukin-15 for cancerRadiation meets immunotherapy - a perfect match in the era of combination therapy?Toxicities of Immunotherapy for the PractitionerUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?Immunotherapy for Bone and Soft Tissue SarcomasNatural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsBiologics in dermatologic therapy - an update.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanomaNew insights into IL-12-mediated tumor suppression.The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsetsThe emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Melanoma: Molecular Pathogenesis and Therapeutic ManagementCorrelation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaIL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Comparison of vascular leak syndrome in mice treated with IL21 or IL2Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.Expression, Identification and Characterize of CD25-Binding Epitope Modified Human IL-2 in Pichia pastoris.Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.Evaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine.Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Cognitive and Affective Symptoms Experienced by Cancer Patients Receiving High-Dose Intravenous Interleukin 2 Therapy: An Integrative Literature Review.Combining radiotherapy with immunotherapy: the past, the present and the future.Immunotherapy of advanced renal cell carcinoma: Current and future therapies.Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy.Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.Delivering safer immunotherapies for cancer.Advances on immunotherapy in genitourinary and renal cell carcinomaCardiotoxicity of cancer chemotherapy: identification, prevention and treatment.A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapyA phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma.Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.Regulatory T cells control toxicity in a humanized model of IL-2 therapy.
P2860
Q24598259-E016B481-4ADE-443F-883D-1106CEFF1FB0Q24601008-0A38B2D1-E811-4FDB-B2DE-1A17B3D48CB5Q26830709-C2358543-B699-433F-A34A-2413A9D4658AQ27005913-E32FC69C-D48C-44CD-B789-E461928C8176Q27008140-AC6637D5-2BB1-4AB3-9FC1-77A0C0D0DB50Q27691824-98C98797-FC18-44A5-BACD-C8FC796870D3Q28073154-70CB129F-BC4C-49E6-8086-24E8F5B38931Q28088363-C7727E09-7422-44A3-968B-1B7746B986A2Q33445569-CC222B71-BA61-4AFF-8BEA-09780659983BQ33607620-5EECE463-BF38-4BF5-BBCC-1FB82FD7AB1DQ33667485-7F098046-5701-4375-A5E2-4B9C56C27F49Q34245154-2E09E701-1679-48DB-89D7-E39E02E17F02Q34436897-BB846576-6B02-45A6-974A-70735197F0B5Q34608796-2497E775-E0BB-4744-AF52-4DD5434948D1Q35012607-7F3921C9-C963-46A6-9E6B-AB7668ACBD1EQ35058213-A7A5B82D-853F-4DC2-80D5-4A96C1A2BA78Q35137163-E350B61C-D9BC-4A78-A9C0-4258107112C5Q35621653-47E8BBD2-E265-4D6A-8495-0CB0B64F8F81Q35979037-A6B0D931-3C01-473C-8B96-8CCCF977DFE9Q36360125-9CE8EF7C-22E0-48A4-B350-3277B9D947D2Q36552580-59982FC3-9F6F-44CD-9FA1-4C6A0D187F4AQ36595426-8C87D961-8EEA-4133-B391-59A58BA785C3Q36684345-D856222C-3D19-4BBA-92DB-35E979E09351Q36946354-7FE07A94-28CF-4806-BBAB-3C8154DE0DB0Q37515861-AE6EE01F-B521-4915-953D-153263D0A47CQ37611373-08A338FC-4D2D-4E94-A97A-33CEC02B677EQ37718529-0E82F963-B50F-4995-8FF7-9D6446DBE9BDQ38636573-04092AC4-8FA9-4426-A658-5663FD2072BFQ38657831-72DC0B45-0DE6-4244-AD92-A4AE3D1AC02FQ38679418-81A814B5-9797-43CD-B603-F0053A7EB633Q38834167-FDBFDC7D-624C-4414-A9B6-1B6C1996DE39Q38942028-938B6510-3E13-488E-8652-133E280F9C5CQ39264898-216CB2D9-86AB-45E8-AE40-B3F641E9B674Q39330984-1B005452-DF1A-4FE7-8B23-76F0A011A28EQ41687389-9ED36BDE-3355-47C2-AA70-7598A12CE9DDQ41704131-232039FA-ADC6-4B7D-A7DC-B3255A528BB1Q41859070-8744D200-AA09-4209-9703-35C4602A2F87Q42657781-5371E767-078B-491C-9B56-263149ABC121Q44944214-0C038E69-E9E3-4CCC-BEAF-BA43ABBC03F2Q47131174-2D16CF2A-268A-41A2-AA21-24B3665F638D
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Managing toxicities of high-dose interleukin-2.
@ast
Managing toxicities of high-dose interleukin-2.
@en
type
label
Managing toxicities of high-dose interleukin-2.
@ast
Managing toxicities of high-dose interleukin-2.
@en
prefLabel
Managing toxicities of high-dose interleukin-2.
@ast
Managing toxicities of high-dose interleukin-2.
@en
P2093
P1433
P1476
Managing toxicities of high-dose interleukin-2
@en
P2093
Janice P Dutcher
Lori Stover
Rowena N Schwartz
P433
11 Suppl 13
P577
2002-11-01T00:00:00Z